Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $133.28 USD
Change Today +0.12 / 0.09%
Volume 48.2K
TARO On Other Exchanges
As of 8:04 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

taro pharmaceutical indus (TARO) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/6/15 - $173.00
52 Week Low
08/21/15 - $124.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

taro pharmaceutical indus (TARO) Related Businessweek News

No Related Businessweek News Found

taro pharmaceutical indus (TARO) Details

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. The company offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. It sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Sun Pharmaceutical Industries Ltd.

1,339 Employees
Last Reported Date: 07/1/15
Founded in 1959

taro pharmaceutical indus (TARO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

taro pharmaceutical indus (TARO) Key Developments

Food and Drug Administration Approves Taro Pharmaceutical Industries Ltd.'s Keveyis for the Treatment of Primary Hyperkalemic and Hypokalemic Periodic Paralysis

Taro Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Keveyis (dichlorphenamide) 50 mg Tablets for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis. Keveyis is the first medicine approved by the FDA for the treatment of primary periodic paralysis, which is estimated to affect approximately 5,000 people in the United States. Taro expects Keveyis will be available for patients during the third quarter of 2015. The company has created the Keys2Care program which will provide a suite of patient support services to ensure people diagnosed with periodic paralysis can receive treatment with Keveyis as soon as possible. As part of this program, the company is working with Diplomat Pharmacy Inc.

Taro Pharmaceutical Industries Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2015

Taro Pharmaceutical Industries Ltd. reported unaudited consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, the company reported net sales of $215,278,000 compared to $130,230,000 a year ago. Operating income was $134,372,000 compared to $54,493,000 a year ago. Income before income taxes was $133,793,000 compared to $51,225,000 a year ago. Income from continuing operations was $103,704,000 or $2.42 basic and diluted per share compared to $46,322,000 or $1.08 basic and diluted per share a year ago. Net income attributable to the company was $103,636,000 or $2.42 basic and diluted per ordinary share compared to $46,098,000, $1.08 per basic and diluted per ordinary share for the same period a year ago. Net cash provided by operating activities was $68,267,000 compared to $35,734,000 a year ago. Purchase of property plant & equipment, net of related grants was $2,393,000 compared to $6,058,000 a year ago. Last year’s quarter net sales were negatively impacted by a $79 million provision for price protection (current quarter’s price protection provision was $14 million). On a pro-forma basis, adjusted for the price protection provisions, the net sales increase would have been 10%. Sales volumes declined 10% as the result of an increase in competitor activity in the U.S. market.

Taro Pharmaceutical Industries Ltd. to Report Q1, 2016 Results on Aug 06, 2015

Taro Pharmaceutical Industries Ltd. announced that they will report Q1, 2016 results After-Market on Aug 06, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TARO:US $133.28 USD +0.12

TARO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $38.42 USD -0.08
Dr Reddy's Laboratories Ltd 4,053 INR -156.35
Glenmark Pharmaceuticals Ltd 1,026 INR -35.80
IGI Laboratories Inc $8.08 USD -0.14
Impax Laboratories Inc $40.31 USD -0.58
View Industry Companies

Industry Analysis


Industry Average

Valuation TARO Industry Range
Price/Earnings 10.5x
Price/Sales 6.0x
Price/Book 3.7x
Price/Cash Flow 10.5x
TEV/Sales 5.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TARO PHARMACEUTICAL INDUS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at